Podcasts about spop

UNAS CUANTAS VERDADES con Mariano Obarrio 03-06-2025 Entrevistas a: Carolina Goedelmann (Jefa Clínica del Laboratorio de Hematología y Hemostasia del Hospital Garrahan) Diego Reynoso @dgreynoso (Director de la Encuesta de SPOP de la Universidad de San Andrés) Cristian Girard @cristiangirard (Director Ejecutivo de ARBA @arba )

Diego Reynoso @dgreynoso (Director de la Encuesta de SPOP de la Universidad de San Andrés) Unas Cuantas Verdades @marianoobarrio

Dr. Evan Yu presents the new evidence-based guideline on genetic testing for metastatic prostate cancer. He discusses who should receive germline and somatic testing with next-generation sequencing technologies, what samples are preferred for testing, and the therapeutic & prognosistc impacts of genetic testing. Dr. Yu emphasizes the need for awareness and refers to areas of active investigation and future research to improve personalized therapies for patients with metastatic prostate cancer.  Read the full guideline, “Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline” at www.asco.org/genitourinary-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02608 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Evan Yu from the University of Washington and Fred Hutchinson Cancer Center, lead author on “Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline”. Thank you for being here today, Dr. Yu. Dr. Evan Yu: Thanks for having me on. Brittany Harvey: Great. Then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the entire guideline, including Dr. Yu, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, Dr. Yu, to start us off on the content of this guideline, could you first provide an overview of both the purpose and scope of this guideline? Dr. Evan Yu: Yeah, absolutely. So I think the one key thing to recognize is that prostate cancer is the highest incidence of all cancers in males. Additionally, it's the second highest cause of mortality in males, and that's about 35,000 deaths in 2024. So with that being said and done, it's a disease where we need to do better. And part of that is recognizing that we now have many targeted therapies, precision medicine type of therapies, but unlike a lot of other cancers out there, prostate cancer patients are not always getting sequencing, next generation DNA sequencing, let's say, to identify both inherited and also spontaneously develop what we call somatic mutations in their tumor. And I suspect that's partially because other cancers like breast cancer, we're so used to- in the first line, you present the patient, you throw out their estrogen receptor status, progesterone receptor status, HER2, ER/PR HER2; in lung cancer it's EGFR, ALK, ROS1, etc. In things like prostate cancer, things like BRCA2 have major important patient treatment implications and potentially family counseling and downstream cascade testing implications. But it hasn't made their way into that first-line presentation yet. And for that reason, there are some studies out there that show that testing in the community may be as low as 15% of patients with metastatic prostate cancer. We want to bring awareness to that and hopefully increase testing down the road so that we can better help our patients with metastatic prostate cancer. Brittany Harvey: Absolutely. It's important to get these targeted therapies to the patients who can benefit most. Using that context, I'd like to next review the key recommendations of this guideline across the six clinical questions that the panel addressed. So, starting with: Who should receive germline testing with next generation sequencing technologies? Dr. Evan Yu: Yeah. We think that it's common enough that everyone with metastatic prostate cancer should receive germline genetic testing. And the reason for that is there have been studies that have looked at this and have shown that 12% of men with metastatic prostate cancer have some sort of inherited germline mutation in a gene, mostly DNA repair genes. But 12% have something that is inherited and that loved ones, first degree relatives, siblings, offspring might have also inherited. Now, most of these are in the DNA repair genes, but that being said and done, there's not only treatment implications for the patient, where there are newer drugs that that patient could get treated with, but other loved ones that might have inherited these gene mutations, that these things can cause other cancers as well - not just prostate cancer, but breast cancer, endometrial cancer, ovarian cancer, pancreatic cancer. So, it's very important to test, with as high of an incidence as 12%, to test, and if you identify it in a patient, it's our job to talk to the patient about it and talk to them about the pros and cons of family counseling and talking to their loved ones and potentially having their loved ones get tested. Because if they test positive, then their doctors may want to know and may screen them very, very aggressively and differently for a whole host of other cancers. And the whole idea is you find the cancer very early and cure the patients before the cancer really takes hold and has the ability to spread so we can save a lot of lives down the road. Brittany Harvey: Absolutely. This germline testing is important not just for the patient, but has wider implications for their families as well, as you mentioned. So then, beyond those recommendations for germline testing, which patients should receive somatic testing with next-generation sequencing technologies? Dr. Evan Yu: So let's talk a little bit about somatic testing. So germline again, as we know, is inherited. The patient inherited it in every single cell in their body, then it becomes very easy, many of these are cancer predispositions for them to lose the other allele and then to have biallelic loss and then develop the cancer. Now, somatic just means it spontaneously occurred. Certainly, it's not going to occur in every cell in the body, but you can get one hit, lose one allele and then lose the other allele. And if that gene is truly carcinogenic and leading to that cancer, then that can have implications potentially for treatment as well. So we recommend that all patients with metastatic prostate cancer also undergo somatic next-generation sequencing testing. We recognize that at this point in time it's only those with metastatic castration-resistant prostate cancer or hormone-resistant prostate cancer, which is a later disease state where there are drugs that may target those mutations, for instance, like PARP inhibitors, but that early identification for a patient population that's fit and that can benefit from these therapies makes sense so that you know it's in place already and you have your treatments outlined and mapped out for the future. So we recommend it for everybody - somatic testing also for everyone with metastatic prostate cancer. Brittany Harvey: Understood. And then when patients are receiving that somatic testing, what is recommended for somatic testing? Primary tumor archival tissue? Fresh metastatic biopsy tissue? Or circulating tumor DNA testing? Dr. Evan Yu: We recommend that in the initial setting when you're first diagnosed, that archival tissue samples are fine and preferred. But circulating tumor DNA is good when there's no accessible archival tissue, or if the archival tissue, let's say, is very old and it's been sitting around for a long time, or you can't get it anymore because it's many years back when maybe a patient had a prostate needle biopsy. So if it's not accessible, then we recommend ctDNA. We believe that is preferred and also that ctDNA is recommended in a situation where you can't easily biopsy a metastatic site. Sometimes it's just not in a safe area to go after. Sometimes it's just a small lesion. So in general, we recommend tissue when available, and when we think that the tissue sample will yield clean results, if not, then we recommend doing ctDNA at that point in time. Brittany Harvey: So you have described who should get germline and somatic genomic testing. But what are the therapeutic impacts of this germline or somatic testing for single gene genetic variants? Dr. Evan Yu: We pulled this panel together and we met like every single month for like 12 months straight, and part of it was to review the literature. And as part of this literature review, we were able to pull a whole bunch of different trials. I think there was like 1713 papers we identified in the literature search. Eventually, we narrowed it down because with ASCO, we want to present the data with the highest level evidence, level 1 evidence, randomized controlled prospective data. And after reviewing 1713 papers, we narrowed it down to 14 papers. With those 14 papers, if you look at it, there are a lot of things that we think may have implications for treatment or prognosis, but we didn't feel was the highest level of evidence that we could support. So the things that have the highest level of evidence that we can support are certain DNA repair gene alterations, especially BRCA2, and treatment with PARP inhibitors because there are many PARP inhibitor prospective trials that show progression-free survival benefit and even overall survival benefit. And so that's the type of study that achieved the level of evidence that we could include. So I would say BRCA1 and BRCA2 highest level of evidence and PARP inhibitor use also is included in that. Brittany Harvey: Understood. I appreciate you reviewing those therapeutic options. So then, the last clinical question, which you just touched on briefly, but what are the prognostic impacts of germline and/or somatic testing? Dr. Evan Yu: Whenever you do testing, especially if you use panel testing, you find a lot of information. There's a lot of different mutations and some of which are VUSs (variants of unknown significance) where we don't quite know what it means yet, but we can track that, especially if it's germline. But with somatic, we find lots of things that have implications, but maybe just not treatment implications. A perfect example is p53. p53 is one of the most common tumor suppressor gene mutations on all cancers, but in prostate cancer they can occur and they can usually occur late, although there can even be germline inherited p53 alterations. There's no treatment that targets p53 right now, but we know that if you have a p53 mutation that those patients may have more aggressive disease and that prognostic information is important to give to the patient. And I think it's important for future clinical trial design and direction. So we do not recommend making treatment recommendations or changes based on these prognostic only biomarkers at this point in time. But we do recommend that, based on this, we can design intensification trials for those patients who have these poor risk biomarkers and de-intensification trials for patients who may have a good risk biomarker. So for instance, SPOP is a gene where we think these patients may have better outcomes, they might respond better to certain hormonal therapies like abiraterone. I say might because the level of evidence isn't quite there. But what I would say is that these prognostic only biomarkers, we just don't think they cut the mustard yet to be able to make treatment decisions. But we do think that they can drive counseling for the patient and potential selection and trial design for the future to say, “Okay. This is a patient population that has a more aggressive cancer. We need to be more aggressive in treating these patients.” “This patient population might have a less aggressive cancer. Maybe we can de-intensify and say side effects and quality of life may be better for the patients.” Brittany Harvey: Definitely. It's important for thinking through how to personalize care for these patients. So then you've talked about this a little bit in talking through the recommendations, but could you expand on what is the importance of this guideline and how it will impact both clinicians and patients with metastatic prostate cancer? Dr. Evan Yu: Yeah, I think the number one thing is awareness. I think the data's out there and people that are in my field, they know this. But by evidence of the fact that it's not first-line presentation lingo that everyone's talking about things like BRCA status, it means it hasn't necessarily disseminated all the way through. So it's increasing awareness of the fact that both germline and somatic alterations can occur and that these may have impacts on the patient for their treatment and their prognosis, and basically to increase testing for the future. I really think that in the future, there'll be other reasons that we may want to serially even retest and we may find that there may be mutations that develop as mechanisms of resistance that might guide therapy down the road. So we need to get people to start doing this for everyone with metastatic prostate cancer, because someday we might be doing it not just once, but over and over again. Brittany Harvey. Absolutely. We hope this guideline reaches a wide audience and that these recommendations can be put into practice. Finally, you've talked about how not all the data in the field has yet risen to the level of evidence that made it into the guidelines. So what are the outstanding questions in future research areas for both germline and somatic genomic testing for metastatic prostate cancer? Dr. Evan Yu: It was in our discussion, but it clearly- it's not common enough for there to be randomized prospective trials that would reach that level of evidence to make it in this guideline recommendation. But we all know that for any solid tumor, you can get mismatched repair deficiency, microsatellite instability leading to hypermutation or high tumor mutational burden. And that happens in maybe 3 to 5% of patients with metastatic prostate cancer as well. There is evidence and data that these patients can potentially benefit from immunotherapies like pembrolizumab. But again, it's just not common enough for there to be those randomized prospective controlled trials out there. But we mention it because we know it's FDA-approved across all the tumor types, so we felt like we have to mention it because that's something that has treatment implications for the patient. But also, I alluded to this earlier, I think an area of active investigation is the tried and true number one driver of prostate cancer, which is androgen receptor. Testosterone binds to androgen receptors, stimulates it. That's how androgen deprivation therapy works. That's how abiraterone and the amides like enzalutamide, apalutamide, darolutamide, that's how they all work. But even beyond that, we're starting to identify that maybe 15%, 20% of patients with metastatic castration resistant prostate cancer have androgen receptor mutations. And there are newer classes of therapies like androgen receptor degraders like CYP11A1 antagonist that lead to complete adrenal annihilation of other steroid hormones that might promiscuously stimulate these androgen receptor mutants. These things develop as mechanisms of resistance, and in the future, we might want to serially test- and that's an active area of investigation in the future, to say you've been treated, let's say, with androgen deprivation therapy and abiraterone for years. There are certain mutations that might develop as a resistance mechanism. We might need to serially test somebody because you didn't have that mutation earlier on, but later in the disease course you might. And then there might be a new drug X out there that we would want to use. Again, we need the data, we need the randomized prospective controlled trials, but they're happening out there. And somewhere down the road we may rewrite this guideline and have a lot more recommendations to add to it. Brittany Harvey: Yes, we'll look forward to more research in this field to better provide targeted therapies for patients with metastatic prostate cancer across the treatment paradigm. And we'll look forward to report outs from those trials that you mentioned. So I want to thank you so much for your work to develop this guideline and thank you for your time today, Dr. Yu. Dr. Evan Yu: Thank you so much. It's wonderful to be here today. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Diego Reynoso @dgreynoso (Director de la Encuesta de SPOP de la Universidad de San Andrés) con @HugoE_Grimaldi

WE ARE BACK FROM HIATUS!!! And we sure did miss you, queerfam. This episode is very close to both our hearts, and we hope you will receive it with love, even if it challenges you in some ways. Instead of our usual post-season race roundtable, today we are discussing Israel & Palestine, & our relationship to the current war on Gaza as Antizionist Jews. With us is special guest Kaia from the Western MA chapter of Jewish Voice for Peace. We'll discuss our personal histories & how we came to consciousness on this topic, as well as some pretty clear parallels between SPOP & our lived experiences of Israel/Palestine. There are a LOT of links in today's show notes, so please use them! They're WICKED EDUCATIONAL.    We will return with regular S5 coverage in late June 2024.   Patreon: https://www.patreon.com/heyadoracast   Meff's Audio Engineering Class GoFundMe: https://bit.ly/audiomeff   Find more info at HeyAdora.gay or on Twitter, Instagram, and TikTok @heyadoracast. Send us your thoughts and feelings at heyadoracast@gmail.com. LINKS TO LEARN MORE! Take action:  https://www.jewishvoiceforpeace.org  https://www.ifnotnowmovement.org   Resources for Education, & Citations: Manufacturing Consent (Noam Chomsky & Edward Herman): https://tinyurl.com/7e7eb75a Covering Islam (Edward Said): https://tinyurl.com/nyeu7he2 The Question of Palestine (Edward Said): https://tinyurl.com/2wcn2zrd Albert Einstein et al letter to the New York Times (Dec 4 1948): https://tinyurl.com/4em3kdjy Arthur Balfour was a white supremacist & an antisemite (Jewish Daily Forward, Nov 1 2017): https://tinyurl.com/34bb4d37 Lessons from the Bund: A Socialist, Anti-Zionist, Jewish Movement (Left Voice, Aug 27 2021): https://tinyurl.com/3ptx6vhh The Red Menace is Gone, but Here's Islam ( New York Times, Jan 21 1996): https://tinyurl.com/4f8km72w Israelism documentary (available to stream on AppleTV, Google Play, Amazon Prime & more, starting June 2024): https://www.israelismfilm.com On the Media from WNYC: Israeli TV News Sanitizes the Bombing of Gaza (Jan 12 2024): https://tinyurl.com/67syjwmv I Drafted the Definition of Antisemitism. Right Wing Jews are Weaponizing it. (The Guardian, Dec 13 2019): https://tinyurl.com/3hk9buve Unpacking the Campus Antisemitism Narrative (Jewish Currents Podcast, April 11 2024): https://tinyurl.com/59dd65zb Jewish Organizing at Columbia's Encampment (Jewish Currents Podcast, April 25 2024): https://tinyurl.com/yc59uczk

WHAT WILL THE AUDIENCE LEARN?We believe that our families and communities are better off when mental healthcare is available at every age. However, older adults face multiple barriers to accessing treatment, including stigma, financial cost, transportation challenges, and language. Negative stereotypes are another barrier, as they teach us that depression is a normal part of aging and that older adults are unable to grow and change. We hope to draw the audience into a conversation about how mental healthcare can support the overall well-being of older adults and strengthen families and communities.EPISODE SUMMARY:About Nancy: Nancy Harvey, LMSW, has served as the chief executive of the Service Program for Older People (SPOP) in New York City since 1990. During her tenure, SPOP has grown from a neighborhood-based agency primarily serving homebound older adults to a regional resource for affordable mental healthcare for adults age 55 and older. A State University of New York system graduate, she holds a B.A. fromSUNY New Paltz and M.S.W. from SUNY Albany. She has been an advocate for increasing access to geriatric mental health care in the region and has developed outreach strategies in partnership with NYCAging, NYC Department of Health and Mental Hygiene, Mount Sinai Health System, New York-Presbyterian

It's the third installment of our now-traditional post-season Race in SPOP discussion! Now BIGGER and BETTER than ever, with 100% more guests!!! Topics include colonization in Etheria, puritanical fan culture, representations of Blackness in villainy, the deep importance of diversity in the writers room, and SO MUCH MORE.   Princess Alba Daza is an emerging Latinx writer, director & consultant based in Montreal, Canada. Alba has been working in the film industry for 10 years. In addition to her work in film, Alba was a producer on the popular podcast Buffering the Vampire Slayer, and has consulted on anti-racism in the film and education sectors. Her art focuses on telling & celebrating the stories of marginalized voices, giving them space to breathe and thrive. Through her work, she is decolonizing popular culture and slaying white supremacy!   Head Sorceress Shawn Harris (who we welcome back!) is an author, educator and huge nerd from Richmond, Virginia. As the mind behind Project Tzimtzum, she creates and runs learning activities that connect curious seekers with Judaism and each other through imagination and play. When she's not coming up with fun new ways to engage people in Jewish text and tradition, Shawn is a huge fan of fantasy, horror and SciFi, and channels her love of these genres through theater and role playing games. Her debut poetry collection, "The Red Door," is a dark fantasy that combines Jewish folklore & mysticism with queer romance. It's currently available on Ben Yehuda Press.   BUY SHAWN'S BOOK: https://www.benyehudapress.com/books/the-red-door/   Find Project Tzimtzum on Twitter: https://tinyurl.com/yk5yn5hk   Find Alba on Instagram: https://tinyurl.com/2p8493em   Hey Adora on Patreon: https://www.patreon.com/heyadoracast   Find more info at HeyAdora.gay or on Twitter, Instagram, and TikTok @heyadoracast. Send us your thoughts and feelings at heyadoracast@gmail.com.

Rem and Sam chat about Mahomes vs Burrow's heavyweight matchup, what Joe Burrow should do about his contract, the Eagles destroying the Niners, Shannahan "What-Ifs", as well as Andy Reid's argument for GOAT coach (00:01) before focusing on some off-season storylines including the Colts dysfunction, the Ravens franchise tagging Lamar Jackson and Tom Brady retiring (47:34). Rem and Sam then discuss Joel Embiid not being an all-star starter, changing the roster format, the reason for the lack a trade buzz, and the amount of young talent in the league (01:21:57) before wrapping up with Ryan Reynolds 'Soccer Corner' (01:49:18) and more! Follow 'Rem and Sam' for the latest in sports, movies, music, and more! Follow the show on Instagram @remandsam Check out SPOP - music "Sticks and Stones" (prod. Kaleidoscope) -

Rem and Sam rant about Josh Allen's performance against the Bengals, the Jags hanging with the Chiefs and a bright Jacksonville, as well as QB question marks in the NFC East surrounding Dak Prescott and Daniel Jones. Then Rem and Sam preview the championship week matchups between Mahomes vs Burrow and the Niners vs Eagles. Rem and Sam quickly buzz around the NBA discussing the Lakers trading for Rui Hachimura, Joe Mazzulla's coaching performance, and Kawhi's return, as well as Mbappe ‘Soccer Corner' and more! Follow Rem and Sam for the latest in sports, movies, music, and more! Follow the show on Instagram Check out SPOP - music: “Soak it Up” (prod. Ven Adams) -

Rem and Sam are thrilled to hear Damar Hamlin was released from the hospital. They then discus Aaron Rodgers' future in Green Bay, fill out their playoff brackets and give their Super Bowl picks, rant about the SEC and the CFP, assign all-nba teams at the halfway point in the season, recap Sam's trip to Denver, and more! Follow 'Rem and Sam' for the latest in sports, movies, music, and more! Follow the show on Instagram! Check out SPOP! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

https://psychiatry.dev/wp-content/uploads/speaker/post-11330.mp3?cb=1672316627.mp3 Playback speed: 0.8x 1x 1.3x 1.6x 2x Download: SPOP loss of function protects against tauopathy – PubMed Randall J Eck et al. PNAS. 2023. The pathological accumulation of the microtubuleFull EntrySPOP loss of function protects against tauopathy – PubMed

It's our second Race in SPOP talk with Head Sorceress Shawn! Topics include race in trauma narratives, the social construction of "the other" in Western tropes, how anti-Asian bigotry and the stereotype of the "model minority" plays into fandom perceptions & judgements of Glimmer, and how white men with dreads are the absolute worst-- EVEN IN SPACE. Tasty links!!! BUY SHAWN'S BOOK! The Red Door: a dark fairy tale told in poems https://www.benyehudapress.com/books/the-red-door/ In Defense of Glimmer: https://youtu.be/48KE-45XdqM   Patreon: https://www.patreon.com/heyadoracast   Find more info at Heyadora.gay or on Twitter, Instagram, and TikTok @heyadoracast. Send us your thoughts and feelings at heyadoracast@gmail.com.

Hey Adora will be at FlameCon 2022!! Join us for a LIVE TAPING of episode 3x03, "Once Upon a Time in the Waste" (aka CATRA IN A LEATHER JACKET). Saturday August 20th at 12:45pm in panel room A. There will be a meet & greet immediately following the show, where you can schmooze with us and talk about all things SPOP, and be the first of your friends to score a COOL AND SHINY Hey Adora sticker. Come gay scream with us!!!   Tickets and Flamecon info at: https://www.flamecon.org   Find more info at Heyadora.gay or on Twitter, Instagram, and TikTok @heyadoracast. Send us your thoughts and feelings at heyadoracast@gmail.com

Meff & Jenny chat with Head Sorceress Shawn in our inaugural dialogue on race & SPOP. It's gonna get wicked nerdy. Head Sorceress Shawn is a playwright, author, and a huge nerd. She is the creator and facilitator of the Queer Women's Torah Workshop. Her debut collection of story-poems, The Red Door, was a semi-finalist for the Cave Canem Poetry Prize, and will soon be published by Ben Yehuda Press.  Her non-fiction writing about living at the intersection of Black and Jewish has been featured in Tablet Magazine and the Tribe-Herald. She is currently developing Project Tzimtzum, inspired by theater and role-playing games. Project Tzimtzum aims to create spaces for playing, dreaming, learning, and making within the Jewish world and beyond.  Shawn can be found on Twitter @ProjectTzimtzum Patreon: https://www.patreon.com/heyadoracast Find more info at Heyadora.gay or on Twitter, Instagram, and TikTok @heyadoracast. Send us your thoughts and feelings at heyadoracast@gmail.com.

In elementary school, Dillon's first office was in his parents' garage where he made miniature skateboards, which were the beginnings of him selling products internationally. In college at the University of Southern California, him and his co-founder, Jarett Chen, created a location-based messaging platform called Spop. They created UNUM to help solve their marketing and creative workflow for Spop because they couldn't afford to hire a creative agency. Today, more than 16 million people in over 190 countries have used UNUM to manage their social media, from big brands to celebrities. Links to learn more about Dillon Morgan:Dillon's LinkedInUNUM's WebsiteFollow us: twitter.com/wistiaSubscribe: wistia.com/series/talking-too-loudLove what you heard? Leave us a review!We want to hear from you! Write in and let us know what you think about the show, who you'd want us to interview on future episodes, and any feedback you have for our team.

"Imagine the Health class where they share the cautionary tale of melting your boyfriend to promote celibacy. Finally that scene from Mean Girls makes sense." In the sixteenth episode of The Hosie Show, Vi, Ri, & Bri share their review and analysis of season 3 episode 16 "Fate's A Bitch, Isn't It?". Topics include: • Malivore the glorified vacuum • how Legacies can do better • how children's shows accomplish what Legacies cannot (ft. SPOP, ATLA, Adventure Time and more) • Rewriting the series ("Imagine if Legacies....") • theories & predictions for season 4 and beyond! Recorded June. 28, 2021. --- Send in a voice message: https://anchor.fm/thehosieshow/message

In this episode we had the great honor of being present, spending time, and feeling the laughs and energy of Mike, Addy, and Odin! We've shared the journey of life alongside Mr. Mike Song since our UCI days and the SPOP program - and to continue to connect in pure childlike wonder and reflection 15 years later is really a blessing of life. Along his journey he and Addy found each other, and the world has been better for it ever since. They are soulmates in the purest sense and it emanates when spending time with them, and their most precious good boy, Odin! Being fully present in the moment - we had a few things to flow with, as the podcast stopped recording during the deepest and most reflective part for 30 minutes, and we noticed right as we had gotten through that part. I guess it was meant for it to be lived and experienced, and not recorded! Also, Yooney's mic wasn't working as we noticed in the playback, so it all lead us to one conclusion: A part 2 with Mike, Addy, and Odin! But enjoy a truly soul rejuvenating time with these two. 

Our long SPOP review finally comes to a close. Today we discuss Horde Prime the evil church man, Shadow Weaver, and Catradora of course. Thank you She-Ra for giving us SO MUCH queer content to talk about. It's really been so much fun. Thanks for reminding us why we must be strong, cuz we're gonna win in the end.

Let's chat about Bow & Glimmer's similarities in their sortings, and why it leads to such a disastrous break between them in the penultimate season; about why Catra has a hard time understanding Adora's decisions and loyalties in a new context; about how Adora puts her faith in powers external to her (her battle plans, her sword) when the real She-Ra lives inside her. Shadow Weaver, Bow, and our host Kat share a Secondary sorting -- and this whole television show is FILLED with Gryffindors. Give us a listen, and bring any questions, comments, or ideas to sortinghatchats.tumblr.com or sortinghatchats.wordpress.com. And if you liked this episode, consider donating to a charity that defends and promotes trans rights, like the ACLU or the National Center for Transgender Equality.

As we near the end of our podcast, we wanted to put a nice bow on our time covering She-Ra and the Princesses of Power, and fortunately, Dreamworks was down to help! In this, the first of two Twitch streams we're calling the "Exit Interviews," we've got a bevy of guests from SPOP ready to answer burning fan questions like "could Angella be alive?" and "does Catra shower?" This interview features:Jen Bennett (director)Josie Campbell (story editor)Phil Lomboy (editor)Noelle Stevenson (executive producer)Sharon Sun (board artist)M. Willis (writer)The second part of these streams is happening Wednesday, 8/26 at 5:30 PM PST! You can catch it over at twitch.tv/ericcgarneau. 

Are you spending hours creating, recording, and editing videos for only a handful of views?Or maybe you ARE getting views but people aren’t breaking down the door to work with you.Viewership Founder, Adam LoDolce, is sharing his 4 step “SPOP” process that helps businesses successfully launch their channel, gain subscribers, gain views and have an IMPACT beyond numbers. Learn Adam’s 4-step YouTube marketing method that helped Neil Patel grow his channel from 10k subscribers to 220k in a year on this week’s episode of the Garlic Marketing Show. What You’ll Learn:4 Steps to Grow Your View Count and ChannelThe One Fundamental for being successful on YouTubeWhy You Should Batch Your VideosHow to Maintain Consistency when Creating and Uploading Videos See acast.com/privacy for privacy and opt-out information.

Hosts: Jon Kallis, Katy Haile, Martin Penny, Josh De Lioncourt, Leanne Hannah Topics of power: On the edge of greatness! DreamWork's She-Ra and the Princesses of Power has debuted on Netflix We review season 2! Masters Cast www.MastersCast.com Jon Kallis, Katy Haile, Martin Penny, Josh de Lioncourt, Leanne Hannah Episode 70 Subscribe to our podcast for free via Apple Podcasts, Spotify, Google Play

Hosts: Jon Kallis, Katy Haile, Martin Penny, Josh De Lioncourt, Leanne Hannah Topics of power: On the edge of greatness! DreamWork's She-Ra and the Princesses of Power has debuted on Netflix We review season 2! Masters Cast www.MastersCast.com Jon Kallis, Katy Haile, Martin Penny, Josh de Lioncourt, Leanne Hannah Episode 70 Subscribe to our podcast for free via Apple Podcasts, Spotify, Google Play

Meet the amazing, Billy Koh!Billy Koh is one of the most instrumental and influential figures in the Asian Chinese-Pop (C-Pop) music industry. Having previously founded Ocean Butterflies - a highly successful comprehensive independent music company in Asia whose businesses include record labels, music production, and more - Billy now works to tackle music rights issues in China as founder of Amusic Rights Management.Over the course of his 30-year long music career, Billy has produced more than 200 albums with many hits. He is the mentor who discovered & produced many successful Asian acts including Kit Chan, A-Do, JJ Lin, BY2 and Amuyi. Apart from speaking at international forums including (3 times in) MIDEM, TEDx, MacWorld Asia, Canadian Music Week, MaMA Festival and MU:CON, Billy has been judging for many popular TV talent shows including "I am a Singer", “Sound of My Dream”, "Supper Boy" in China, “One Million Star” and “Chinese Idol” in U.S., “Asia Song Festival” in South Korea, “Asia New Singer Competition” in Hong Kong, “Project SuperStar” and “SPOP sing” in Singapore.We caught up with Billy at the Berkelee China/US Music Summit to speak about the evolving C-pop landscape and the role that society, law, and culture play in determining regional hits and music creation.Important LinksLinkedinAmusic Rights Official WebsiteOther Awesome Interviews with BillyBlogTalk InterviewTEDx Tencent (Chinese)Entertain Naver Interview (Korean)Shownotes:2:19 - What brings you to the US/China Summit?3:42 - How has China progressed over the last 10 years?5:34 - Why hasn’t there historically been better IP protection in China?7:02 - What has China been doing to combat piracy?8:02 - How is improved copyright protection impacting the music coming out of China?9:04: How do we produce new hits in China over the next few years?10:11 - How do you think the Chinese market can incorporate the changing dynamics of what a hit is to move the Chinese music market forward? What is pop to you?12:34 - How have pops changed over the years?14:04 - Do you think that the background context of the time/environment of the artist plays a role in the success of modern songs to any degree? What is the trajectory of music in China given the different ways of creating music?16:00 - what is going to be the driving force behind music creation in China moving forward?17:04 - Music’s cultural underpinnings in the connected, internet era18:44 - What makes Chinese music Chinese? Can it be classified?21:09 - How does the culture translate into the music being created?

In our fifty-sixth Minute, the gals of Mystic Pizza boost Bill's work truck from the Peg Leg Pub parking lot and drive off into the night screaming along the words to R.E.S.P.E.C.T. Your usual Pizza Mystics are joined once again by producer Steve, giving you up to the minute (when it was recorded) info on the results of the Alabama special election, and the progress of their UberEats delivery driver. Not gonna lie, this one was a mess every step of the process. Special Guest: Steve Richardson

In questa puntata presentiamo SPOP - Festiva dello sport popolare, torniamo alla carica con la "pedagogia di montagna" e vi facciamo sentire come "suona" un ghiacciaio.Che volete di più?

In questa puntata presentiamo SPOP - Festiva dello sport popolare, torniamo alla carica con la "pedagogia di montagna" e vi facciamo sentire come "suona" un ghiacciaio.Che volete di più?

Our 1st show since the news broke around the end of the game. Join us in celebrating the game that has brought us together over the last 4 year. – SpOp 36 launched – Adam Warlock the final reward hero – White Tiger became the last General Release hero – we share some great memories […] The post FTH #157 "Tanks for the M:AAmories" first appeared on From the Helicarrier.

Our 1st show since the news broke around the end of the game. Join us in celebrating the game that has brought us together over the last 4 year. – SpOp 36 launched – Adam Warlock the final reward hero – White Tiger became the last General Release hero – we share some great memories […]

Our 1st show since the news broke around the end of the game. Join us in celebrating the game that has brought us together over the last 4 year.- SpOp 36 lauched - Adam Warlock the final reward hero- White Tiger became the last General Release hero- we share some great memories and stories of the game.- The feels come into play starting with the audio segments from everybody and continuing on throughout the emails.We have one more show to go so get those emails in.

Listen Up! Show 66 is laden with:Yes, Floyd Landis has a case - see it onlineOrigins of band namesTune 1: Cast That Ballot by the Lascivious BiddiesVotes...ugh!  Good God!  What are they good for?  Absolutely nuthin'!Squeezing the middle classJub numbers are up - salaries are downWhat next?  Watch Fight Club and see.Tune 2: Spop by The Four BagsOn Film: Once in a Lifetime: The Extraordinary Story of the New York CosmosDiscuss this show, here.